Lunai Bioworks (LNAI) Stock Soars 81% on Nasdaq Compliance Restoration

17-Jun-2026 Blockonomi

Key Highlights

  • LNAI shares skyrocketed 80.88% to reach $5.15 during after-hours trading on Tuesday
  • On June 11, Nasdaq’s Hearings Panel verified that Lunai Bioworks has satisfied the exchange’s $1.00 minimum bid price requirement
  • A strict one-year monitoring phase begins immediately for the biotech company
  • Should LNAI dip beneath $1.00 during this monitoring window, Nasdaq may delist the stock without offering a grace period
  • Over the trailing twelve months, shares have plummeted 90.11% and continue trading near annual lows

Shares of Lunai Bioworks (LNAI) exploded 80.88% higher to $5.15 during extended trading hours on Tuesday. The dramatic rally followed an SEC filing revealing that Nasdaq had officially recognized the company’s return to compliance with the exchange’s $1.00 minimum bid price standard.


LNAI Stock Card
Lunai Bioworks Inc., LNAI

Earlier in Tuesday’s regular session, LNAI had already gained 9%, finishing at $2.84 before the explosive after-hours movement took hold.

The announcement stems from communication the company received from a Nasdaq Hearings Panel on June 11. The panel verified that Lunai had successfully fulfilled requirements under both the Bid Price Rule and specific conditions outlined in extension letters dated April 20 and May 12.

Regaining compliance wasn’t a simple process. The company needed to fulfill requirements from two distinct extension letters before achieving its reinstated status.

Strict Monitoring Phase Now in Effect

Having regained compliance, Lunai now faces a rigorous one-year monitoring phase. Throughout this period, Nasdaq will actively track the stock’s performance.

Should LNAI’s bid price fall below the $1.00 threshold at any time during this twelve-month span, Nasdaq will immediately issue a delisting determination — with no opportunity for a grace period or compliance strategy.

The company does have one recourse available: submitting a request for a new hearing with the Nasdaq Hearings Panel. Such a filing would temporarily halt any suspension or delisting proceedings until the panel renders its final verdict.

Tuesday’s trading activity was extraordinary. Volume reached 19.33 million shares — approximately 33.4 times higher than the typical daily average of 578,990 shares.

The Relative Strength Index registered at 50.69, indicating a neutral market position.

Long-Term Performance Remains Severely Negative

While Tuesday’s surge provided temporary relief, LNAI’s overall trajectory remains deeply troubling. The stock has declined 90.11% over the past year.

The stock’s 52-week range spans from a high of $31.75 down to a low of $1.21. Current trading levels remain dangerously close to that annual floor.

Following the after-hours movement, Lunai’s market capitalization stood at roughly $12.90 million.

Short interest currently represents 8.72% of available shares, while technical indicators flash a “Sell” signal.

While the restored Nasdaq listing provides continued exchange access, the twelve-month monitoring requirement creates sustained pressure on leadership to maintain share prices above the critical $1.00 level.

The SEC disclosure confirming the compliance achievement served as the primary driver behind Tuesday’s explosive after-hours rally.

The post Lunai Bioworks (LNAI) Stock Soars 81% on Nasdaq Compliance Restoration appeared first on Blockonomi.

Also read: Novo Nordisk (NVO) Stock Under Pressure as Hackers Leak Stolen Data After Ransom Rejection
WHAT'S YOUR OPINION?
Related News